LifeFlow, Inc. heals arteries and restores their natural flow and flexibility.

Unlike other companies in the $3+ billion coronary stent market, LifeFlow’s products are BiotransformableTM. By releasing healing drugs over several months and interacting with the artery to biotransform into a flexible micro mesh, LifeFlow’s products overcome the shortfalls of incumbent metal stents and new biodegradable stents currently in clinical trials.

LifeFlow’s Biotransfromable product has successfully completed initial animal testing. An investment of six million dollars is sought to accelerate development of the product into and through phase I clinical trials.

Product development to date has been funded by two Small Business Innovation Research (SBIR) grants from the National Science Foundation (NSF) and from seed investments. The NSF grant was due in part to “an impressive publication and patent record”* of the primary investigator and “the significant impact on the US market for coronary stents.”*

The officers of LifeFlow have strong business operations and financial experience, a track record of successfully commercializing inventions and expertise in polymer science and medicinal chemistry.

LifeFlow has an exclusive license for coronary stents based on materials developed by Ablitech, Inc. (www.ablitech.com). The intellectual property was initially developed by the University of Southern Mississippi’s world renowned Polymer Science and Engineering School.

* Quotes from the reviews of the funded SBIR proposal submitted by Ablitech to the NSF.